A multicenter phase II study of cetuximab in combination with chest radiotherapy and consolidation chemotherapy in patients with stage III non-small cell lung cancer

Lung Cancer

Volumn 81, Issue 3, 2013, Pages 416-421

  Ramalingam, S S ^a   Kotsakis, A ^b   Tarhini, A A ^c   Heron, D E ^c   Smith, R ^c   Friedland, D ^c   Petro, D P ^c   Raez, L E ^d,g   Brahmer, J R ^e   Greenberger, J S ^c   Dacic, S ^c   Hershberger, P ^c   Landreneau, R J ^c   Luketich, J D ^c   Belani, C P ^f   Argiris, A ^g  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^c UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^d Memorial Cancer Institute   (United States)

^e JOHNS HOPKINS UNIVERSITY   (United States)

^f PENN STATE CANCER INSTITUTE   (United States)

^g University of Texas Health Science Center   (United States)

Author keywords

Cetuximab; Chemotherapy; EGFR; Non small cell lung cancer; Radiotherapy

Indexed keywords

CARBOPLATIN; CETUXIMAB; PACLITAXEL;

ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL ARTICLE; CONSOLIDATION CHEMOTHERAPY; ESOPHAGITIS; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DOSAGE; HUMAN; INFECTION; LUNG EMBOLISM; LUNG NON SMALL CELL CANCER; MALE; NEUTROPENIA; OVERALL SURVIVAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIATION DOSE; RADIATION DOSE FRACTIONATION; RASH; TREATMENT RESPONSE;

CETUXIMAB; CHEMOTHERAPY; EGFR; NON-SMALL CELL LUNG CANCER; RADIOTHERAPY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; COMBINED MODALITY THERAPY; CONSOLIDATION CHEMOTHERAPY; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; RADIOTHERAPY; TREATMENT OUTCOME;

EID: 84881670178     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2013.06.002     Document Type: Article

References (26)

1. Curran W.J., Paulus R., Langer C.J., Komaki R., Lee J.S., Hauser S., et al. Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410. J Natl Cancer Inst 2011, 103(19):1452-1460.
2. Furuse K., Fukuoka M., Kawahara M., Nishikawa H., Takada Y., Kudoh S., et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol: Off J Am Soc Clin Oncol 1999, 17(9):2692-2699.
3. Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004, 350(21):2129-2139.
4. Soda M., Choi Y.L., Enomoto M., Takada S., Yamashita Y., Ishikawa S., et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007, 448(7153):561-566.
5. Baselga J., Arteaga C.L. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J Clin Oncol: Off J Am Soc Clin Oncol 2005, 23(11):2445-2459.
6. Baselga J. The EGFR as a target for anticancer therapy - focus on cetuximab. Eur J Cancer 2001, 37(Suppl. 4):S16-S22.
7. Bonner J.A., Harari P.M., Giralt J., Azarnia N., Shin D.M., Cohen R.B., et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006, 354(6):567-578.
8. Toulany M., Dittmann K., Kruger M., Baumann M., Rodemann H.P. Radioresistance of K-Ras mutated human tumor cells is mediated through EGFR-dependent activation of PI3K-AKT pathway. Radiother Oncol: J Eur Soc Therapeut Radiol Oncol 2005, 76(2):143-150.
9. Chakravarti A., Dicker A., Mehta M. The contribution of epidermal growth factor receptor (EGFR) signaling pathway to radioresistance in human gliomas: a review of preclinical and correlative clinical data. Int J Radiat Oncol Biol Phys 2004, 58(3):927-931.
10. Nasu S., Ang K.K., Fan Z., Milas L. C225 antiepidermal growth factor receptor antibody enhances tumor radiocurability. Int J Radiat Oncol Biol Phys 2001, 51(2):474-477.
11. Rades D., Wolff C., Nadrowitz R., Breunig C., Schild S.E., Baehre M., et al. Radioactive EGFR antibody cetuximab in multimodal cancer treatment: stability and synergistic effects with radiotherapy. Int J Radiat Oncol Biol Phys 2009, 75(4):1226-1231.
12. Hanna N., Lilenbaum R., Ansari R., Lynch T., Govindan R., Janne P.A., et al. Phase II trial of cetuximab in patients with previously treated non-small-cell lung cancer. J Clin Oncol: Off J Am Soc Clin Oncol 2006, 24(33):5253-5258.
13. Ramalingam S.S., Lee J.W., Belani C.P., Aisner S.C., Kolesar J., Howe C., et al. Cetuximab for the treatment of advanced bronchioloalveolar carcinoma (BAC): an Eastern Cooperative Oncology Group phase II study (ECOG 1504). J Clin Oncol: Off J Am Soc Clin Oncol 2011, 29(13):1709-1714.
14. Pirker R., Pereira J.R., Szczesna A., von Pawel J., Krzakowski M., Ramlau R., et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 2009, 373(9674):1525-1531.
15. Lynch T.J., Patel T., Dreisbach L., McCleod M., Heim W.J., Hermann R.C., et al. Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099. J Clin Oncol: Off J Am Soc Clin Oncol 2010, 28(6):911-917.
16. Blumenschein G.R., Paulus R., Curran W.J., Robert F., Fossella F., Werner-Wasik M., et al. Phase II study of cetuximab in combination with chemoradiation in patients with stage IIIA/B non-small-cell lung cancer: RTOG 0324. J Clin Oncol: Off J Am Soc Clin Oncol 2011, 29(17):2312-2318.
17. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92(3):205-216.
18. Tarhini A., Kotsakis A., Gooding W., Shuai Y., Petro D., Friedland D., et al. Phase II study of everolimus (RAD001) in previously treated small cell lung cancer. Clin Cancer Res: Off J Am Assoc Cancer Res 2010, 16(23):5900-5907.
19. Belani C.P., Choy H., Bonomi P., Scott C., Travis P., Haluschak J., et al. Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer: a randomized phase II locally advanced multi-modality protocol. J Clin Oncol: Off J Am Soc Clin Oncol 2005, 23(25):5883-5891.
20. Hanna N., Neubauer M., Yiannoutsos C., McGarry R., Arseneau J., Ansari R., et al. Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and U.S. Oncology. J Clin Oncol: Off J Am Soc Clin Oncol 2008, 26(35):5755-5760.
21. Vokes E.E., Herndon J.E., Crawford J., Leopold K.A., Perry M.C., Miller A.A., et al. Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non-small-cell lung cancer: cancer and leukemia group B study 9431. J Clin Oncol: Off J Am Soc Clin Oncol 2002, 20(20):4191-4198.
22. Vokes E.E., Herndon J.E., Kelley M.J., Cicchetti M.G., Ramnath N., Neill H., et al. Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III Non-small-cell lung cancer: Cancer and Leukemia Group B. J Clin Oncol: Off J Am Soc Clin Oncol 2007, 25(13):1698-1704.
23. Govindan R., Bogart J., Stinchcombe T., Wang X., Hodgson L., Kratzke R., et al. Randomized phase II study of pemetrexed, carboplatin, and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small-cell lung cancer: Cancer and Leukemia Group B trial 30407. J Clin Oncol: Off J Am Soc Clin Oncol 2011, 29(23):3120-3125.
24. Jatoi A., Schild S.E., Foster N., Henning G.T., Dornfeld K.J., Flynn P.J., et al. A phase II study of cetuximab and radiation in elderly and/or poor performance status patients with locally advanced non-small-cell lung cancer (N0422). Ann Oncol: Off J Eur Soc Med Oncol - ESMO 2010, 21(10):2040-2044.
25. Jensen A.D., Munter M.W., Bischoff H.G., Haselmann R., Haberkorn U., Huber P.E., et al. Combined treatment of nonsmall cell lung cancer NSCLC stage III with intensity-modulated RT radiotherapy and cetuximab: the NEAR trial. Cancer 2011, 117(13):2986-2994.
26. Auperin A., Le Pechoux C., Rolland E., Curran W.J., Furuse K., Fournel P., et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol: Off J Am Soc Clin Oncol 2010, 28(13):2181-2190.